



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

Date: 29th May, 2026

To,
The Deputy Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400001.

Sub: Audited Standalone Financial Results for the quarter and the year ended 31st March, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Scrip Code: 586565

Scrip Id: NOVELIX

Respected Sir/ Madam,

Pursuant to the Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (Listing Regulations), the Board of Directors at their meeting held on 29th May, 2026 have considered and approved, the Audited standalone Financial Results of the company for the quarter and year ended 31st March, 2026 along with the report of the auditors thereon.

The Auditors' Report with an unmodified opinion on the said financial results is also attached herewith.

The Board Meeting commenced at 05:00 p.m. (IST) and concluded at 06:30 p.m. (IST).

The aforesaid information is also available on the website of the Company www.novelixpharma.com
We request you to take the aforesaid information on record for dissemination through your website.

Thanking you,

Yours Faithfully,

For Novelix Pharmaceuticals Limited

Venkateshwarlu Pulluru
(Whole-time director)
DIN: 02076871

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



CVS Balachandra Rao & Co.,
Chartered Accountants

Independent Auditor's Report on Audited standalone Quarterly Financial Results and Year to Date Results of Novelix Pharmaceuticals Limited (formerly known as Trimurthi Limited) CIN: L67120TG1994PLC018956, pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
Novelix Pharmaceuticals Limited
(Formerly Known as Trimurthi Limited)
H No: 3-6-237/610, Flat No: 610, 6th Floor,
Lingapur LA Builders formerly known as Amrutha Estates,
Himayat Nagar, Hyderabad, Telangana- 500029.

Report on the audit of Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly financial results of Novelix Pharmaceuticals Limited (Formerly Known as Trimurthi Limited) for the quarter ended 31st March 2026 and the year ended 31st March 2026 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the quarter ended March 31, 2026 as well as the year ended as on March 31, 2026.



D No 3-6-108/1 Flat No:203 Sanatana Eternal. Street No:19, Himayat Nagar Hyderabad 500 029 Telangana
☎ 9849035315, 9010624455

✉ cacvsbala@gmail.com, cvsbala67@gmail.com, 🌐 Website : www.cabrc.in

Branch Office : D.No. 11-33-7B, 2nd Floor. Tatakulavari Street, Samarang Chowk, Vijayawada - 520 001 A P
H.No. 16-2/20/3, Sainiranjan Colony, Dogguvanipalem, Pendurthy - 531 173. Vishakapatnam, A P

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our opinion is not modified in respect of this matter.

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the



aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
4. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matter

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review as required under the Listing Regulations.

As per our report of even date,
For CVS Balachandra Rao & Co
Chartered Accountants
Firm Regd. No: 0075075


CVS Balachandra Rao
Partner
Membership No.204580
UDIN: 26204580YVWFU2764
Date: 29/05/2026
Place: Hyderabad





Novelx Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

Statement of Standalone Audited Financial Results for the quarter and year ended 31st March, 2026

(Rs. In Lakhs except Earning per share)

S. No.	Particulars	3 Months ended	Preceding 3 Months ended	Corresponding 3 Months Ended in Previous Year	Year to Date Figures for Current Period Ended	Year to date figures for Previous year ended
		31.03.2026 (Audited)	31.12.2025 (Unaudited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
1	Revenue					
	a) From operations	2,519.36	4,840.25	2,086.10	13,230.62	3,071.85
	b) Other Income	(0.00)	0.02	-	3.26	1.60
	Total Revenue	2,519.36	4,840.27	2,086.10	13,233.88	3,073.44
2	Expenses					
	(a) Cost of Material Consumed	--	--	--	--	--
	(b) Purchases of stock-in-trade	3,284.31	4,828.08	2,021.61	14,030.37	2,922.25
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(994.40)	(143.18)	6.77	(1,358.89)	35.12
	(d) Employees Benefits expenses	23.90	17.30	0.73	71.83	6.86
	(e) Finance Cost	--	--	--	--	--
	(f) Depreciation amortization expenses	4.61	3.02	2.34	10.11	3.80
	(g) Other Expenses	77.65	6.74	33.59	140.03	93.08
	Total Expenses	2,396.07	4,711.97	2,065.04	12,893.45	3,061.11
3	Profit from ordinary activities before exceptional Items (1 - 2)	123.29	128.30	21.06	340.43	12.33
4	Exceptional Items - Income/ (Expenses)	--	--	--	--	--
5	Profit from ordinary activities before tax (3 +/- 4)	123.29	128.30	21.06	340.43	12.33
6	Tax Expenses					
	(a) Current Tax	32.65	28.80	2.96	83.02	2.96
	(b) Deferred Tax	(0.55)	(0.93)	(0.15)	1.75	
7	Profit/(Loss) for the period (5 -6)	91.19	100.43	18.25	255.66	8.45



Novelx Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelxpharmaceuticals@gmail.com

www.novelixpharma.com



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314101036)

8	A (i) Items that will not be reclassified to profit or loss (net of tax) (ii) Income Tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (net of tax) (ii) Income Tax relating to items that will be reclassified to profit or loss	--	--	--	--	--
9	Total Comprehensive Income, net of tax (7 + 8)	91.19	100.43	18.25	255.66	8.45
10	Paid up equity share capital (Face Value of Rs.10/- each)	2108.50	1721.50	995.00	2108.50	995.00
11	Earning per share (of Rs.10/-each) (Not Annualised)					
	(a) Basic	0.43	0.58	0.18	1.21	0.08
	(b) Diluted	0.32	0.85	0.20	1.75	0.09

Place: Hyderabad
Date: 29-05-2026

By order of the Board
For Novelix Pharmaceuticals Limited



Venkateshwarlu Pulluru

Venkateshwarlu Pulluru
(Whole-time director)
DIN: 02076871

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com
www.novelixpharma.com



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

NOTES TO THE STANDALONE FINANCIAL RESULTS

1. The above Audited Financial Results of the company for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 29th May, 2026.
2. The Company has only one business segment ' Pharmaceutical Research & Analysis and Manufacturing & Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). The Company is not carrying any activity in the segments Investment in Shares, Trading in shares, Foods and Finance.
3. Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4. These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5. The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity ' Pharmaceutical Research & Analysis and Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6. The standalone results of the company will be available on the company's website <https://novelixpharma.com>

Place: Hyderabad
Date: 29-05-2026



By order of the Board
For Novelix Pharmaceuticals Limited

Venkateshwarlu Pulluru
(Whole-time director)
DIN: 02076871

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com
www.novelixpharma.com



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

STATEMENT OF AUDITED STANDALONE ASSETS AND LIABILITIES AS AT MARCH 31,2026

(Rs. In Lakhs)

PARTICULARS		As at 31st March 2026 (Un Audited)	As at 31-March 2025 (Audited)
ASSETS			
1	Non - current assets		
(a)	Property, plant and equipment	152.18	18.57
(b)	Capital work in progress	-	-
(c)	Investment property	-	-
(d)	Intangible assets	192.00	0.00
(e)	Financial assets		
(i)	Investments	4.32	4.32
(ii)	Loans	-	-
(iii)	Other financial assets	-	-
(f)	Deferred tax Assets (Net)	2.71	4.46
(g)	Other non-current assets	-	-
	Total non-current assets	351.21	27.35
2	Current assets		
(a)	Inventories	1,443.22	84.32
(b)	Financial assets		
(i)	Investments	-	-
(ii)	Trade receivables	5,896.15	1,813.69
(iii)	Cash and cash equivalents	295.86	67.86
(iv)	Other balances with banks	-	-
(v)	Loans	983.08	702.31
(vi)	Other financial assets	-	-
(c)	Other Current assests	272.81	25.11
	Total current assets	8,891.12	2,693.29
	TOTAL ASSETS	9,242.33	2,720.65
EQUITY AND LIABILITIES			
1	Equity		
(a)	Share capital	2,108.50	995.00
(b)	Other equity	2,540.34	758.93
	Total Equity	4,648.84	1,753.93
2	Non-current liabilities		
(a)	Financial liabilities		
(i)	Long-term borrowings	432.19	-
(ii)	Deferred tax liabilities (net)	-	-
(iii)	Other financial liabilities	-	-
(b)	Provisions	-	-
(c)	Other non-current liabilities	-	-
	Total non-current liabilities	432.19	
3	Current liabilities		
(a)	Financial liabilities		
(i)	Borrowings	-	-



Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



Novelx Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

(ii) Trade payables	4,025.37	920.11
(iii) Other financial liabilities	-	-
(b) Provisions	135.25	36.60
(c) Other current Liabilities	0.68	10.00
Total current liabilities	4,161.30	966.72
Total Liabilities	4,593.48	966.72
TOTAL EQUITY AND LIABILITIES	9,242.33	2,720.65

By order of the Board
For Novelx Pharmaceuticals Limited

Place: Hyderabad
Date: 29-05-2026



Novelx
Venkateshwarlu Pulluru
(Whole-time director)
DIN: 02076871

Novelx Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



Novelx Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

STATEMENT OF AUDITED STANDALONE CASH FLOW STATEMENT FOR THE PERIOD ENDED 31st March 2026

(Rs. In Lakhs)

Particulars	As at 31-03-2026	As at 31-03-2025
A. Cash Flow from Operating Activities:		
Net Profit before Tax and Extraordinary Items	340.43	12.33
Adjustments for:	-	-
Depreciation	10.11	3.80
Interest & Other Income	(3.26)	(1.60)
Loss on Sale of Fixed Assets	-	-
Loss on Sale of Investments & Property	-	-
Profit on sale of mutual funds	-	-
Operating profit before Working Capital Changes	347.28	14.54
Adjustments for:		
(Increase) / Decrease in Trade Receivables	(4,363.24)	(2,259.35)
(Increase) / Decrease in Inventories	(1,358.89)	35.12
Increase / (Decrease) in Trade Payables	3,105.25	841.24
Increase / (Decrease) in Other Current Liabilities	9.33	-
Short-Term Provisions	21.36	-
Cash generated from Operations	(2,585.63)	(1,382.99)
Cash flow before Extraordinary Items	(2,238.91)	(1,368.46)
(Increase) / Decrease Extraordinary Items and Tax	-	-
Net Cash used for Operating activities	(2,238.91)	(1,368.46)
B. Cash Flow from Investing Activities:		
Purchase of Fixed Assets	(325.60)	(10.61)
Sale of Fixed Assets		
Capital Work in progress		
Sale of Investments	-	302.05
Increase / (Decrease) in Security Deposits - Canara	150.00	1.60
Interest & Other Income	3.26	-
Net Cash flow from Investing activities	(172.34)	
C. Cash Flow from Financing Activities:		



Novelx Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

Increase in Share Capital	1,113.50	185.00
Increase in Share Premium	1,525.75	121.50
Increase / Decrease in Long Term Borrowings	-	-
Share Issue and Preliminary Expenses	-	-
Warrents Issued	-	825.00
Net Cash flow from Financing activities	2,639.25	1,131.50
Net Increase in Cash and Cash Equivalents (A+B+C)	228.00	56.08
Cash and Cash Equivalents as at (Opening Balance)	67.86	11.78
Cash and Cash Equivalents as at (Closing Balance)	295.86	67.86

Place: Hyderabad
Date: 29-05-2026

By order of the Board
For Novelix Pharmaceuticals Limited



Venkateshwarlu Pulluru
Venkateshwarlu Pulluru
(Whole-time director)
DIN: 02076871

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com
www.novelixpharma.com



Novelx Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

Working for Segment Revenue & Segment Profit:

(Rs. In Lakhs)

	Pharma Business	Investment in Shares	Trading in shares	Foods	Finance	Total
I. Revenue						
-Sales	13231					13231
-Other Income	3	0	0			3
	13234	0	0	0	0	13234
	0	0	0	0	0	0
II. Expenditure						
-Purchase	14030					14030
-Cost of Material consumed		0		0	0	0
-Manufacturing Exp	0	0		0	0	0
-Changes in Inventory	-1359	0				-1359
-Employee Benefits Expenses	72					72
-Finance Cost						0
-Depreciation & Amortization Expense	10					10
-Other Expenses	140	0				140
						0
						0
						0
	12893	0	0	0	0	12893
Profit/ (Loss)	340	0	0	0	0	340
Less: Income Tax Paid for Earlier Years						0
	340	0	0	0	0	340
	0	0	0	0	0	0

Verified



Novelx Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com